Peter Carroll, MD

Peter R. Carroll, MD, MPH

Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Phone: (415) 353-7171 (appts)

Box 1711, UCSF
San Francisco, CA 94143-1711

Physician Biography

UCSF Profiles

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Research Funding

  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103
  • September 30, 2008 - July 31, 2020 - UCSF KURe Career Development Program , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12DK083021
  • September 30, 2009 - August 31, 2012 - Effectiveness of Early Stage Prostate Cancer Treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: RC1CA146596
  • September 30, 2006 - August 31, 2012 - Male Reproductive Health Research Career Development Program , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12HD053943
  • September 25, 2000 - June 30, 2010 - UCSF PROSTATE CANCER SPORE , Principal Investigator . Sponsor: NIH, Sponsor Award ID: P50CA089520
  • June 10, 2003 - May 31, 2009 - Molecular Effects of Nutrition Supplements in Prostate , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA101042
  • May 5, 2006 - April 30, 2007 - Active Surveillance for Early Stage Prostate Cancer: Selection, Monitoring , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R13CA121759

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Palmer NR, Carroll PR, Washington SL. Time is on our side - rethinking the concept of time to treatment for prostate cancer. Nat Rev Urol. 2024 Nov 29.  View on PubMed
  2. Fakunle MO, Cowan JE, Washington SL, Shinohara K, Nguyen HG, Carroll PR. Targeted Biopsy Is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2025 Jan; 213(1):34-39.  View on PubMed
  3. Carroll PR. Legends in Urology v31I05. Can J Urol. 2024 Oct; 31(5):11974-11976.  View on PubMed
  4. Patel SA, Patil D, Smith J, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Michalski JM, Wood DP, Hembroff LA, Spratt DE, Wei JT, Sandler HM, Hamstra DA, Pisters L, Kuban D, Regan MM, Wagner A, Crociani CM, Kaplan I, Sanda MG, Chang P, PROST-QA/RP2 Consortium. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747.  View on PubMed
  5. Shee K, Nie J, Cowan JE, Wang L, Washington SL, Shinohara K, Nguyen HG, Cooperberg MR, Carroll PR. Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance. Eur Urol Oncol. 2024 Sep 27.  View on PubMed
  6. Carlsson SV, Carroll PR, Hamdy FC. Reevaluating the Definition of Clinically Significant Prostate Cancer as Grade Groups 2 to 5: An Imperative for Improved Risk Stratification. J Urol. 2025 Feb; 213(2):238-241.  View on PubMed
  7. Starobinets O, Simko JP, Gibbons M, Kurhanewicz J, Carroll PR, Noworolski SM. The impact of benign tissue within cancerous regions in the prostate: Characterizing sparse and dense prostate cancers on whole-mount histopathology and on multiparametric MRI. Magn Reson Imaging. 2024 Dec; 114:110233.  View on PubMed
  8. Mohamad O, Li YR, Feng F, Hong JC, Wong A, El Kouzi Z, Shelan M, Zilli T, Carroll P, Roach M. Delayed definitive management of localized prostate cancer: what do we know? Prostate Cancer Prostatic Dis. 2024 Aug 11.  View on PubMed
  9. Kohlbrenner R, Wu X, Nguyen HG, Cooperberg MR, Chakravarty T, Carroll PR, Hope TA. Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. Radiology. 2024 08; 312(2):e232544.  View on PubMed
  10. Tohi Y, Sahrmann JM, Arbet J, Kato T, Lee LS, Peacock M, Ginsburg K, Pavlovich C, Carroll P, Bangma CH, Sugimoto M, Boutros PC, Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium. Eur Urol Oncol. 2024 Jul 31.  View on PubMed
  11. Nik-Ahd F, De Hoedt AM, Butler C, Anger JT, Carroll PR, Cooperberg MR, Freedland SJ. Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen. JAMA. 2024 07 23; 332(4):335-337.  View on PubMed
  12. Bangma C, Doan P, Zhu L, Remmers S, Nieboer D, Helleman J, Roobol MJ, Sugimoto M, Chung BH, Lee LS, Frydenberg M, Klotz L, Peacock M, Perry A, Bjartell A, Rannikko A, Van Hemelrijck M, Dasgupta P, Moore C, Trock BJ, Pavlovich C, Steyerberg E, Carroll P, Koo KC, Hayen A, Thompson J, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry. Eur Urol Oncol. 2024 Jul 17.  View on PubMed
  13. Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, Carroll PR, Dash A, de la Calle CM, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Tretiakova MS, Wagner AA, Nelson PS, Lin DW. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 2024 06 25; 331(24):2084-2093.  View on PubMed
  14. Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology. 2024 Oct; 85(4):598-613.  View on PubMed
  15. Greenland NY, Cooperberg MR, Carroll PR, Cowan JE, Simko JP, Stohr BA, Chan E. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. Prostate. 2024 Aug; 84(11):1076-1085.  View on PubMed
  16. Liu VN, Van Blarigan EL, Zhang L, Graff RE, Loeb S, Langlais CS, Cowan JE, Carroll PR, Chan JM, Kenfield SA. Plant-Based Diets and Disease Progression in Men With Prostate Cancer. JAMA Netw Open. 2024 05 01; 7(5):e249053.  View on PubMed
  17. Porten SP, Wang EY, Vohra P, Carroll PR, Jahanfard S, Kim NW. Evaluation of URO17® to improve non-invasive detection of bladder cancer. Urol Oncol. 2024 Jun; 42(6):176.e21-176.e28.  View on PubMed
  18. Braun AE, Chan JM, Neuhaus J, Cowan JE, Kenfield SA, Van Blarigan EL, Tenggara I, Broering JM, Simko JP, Carroll PR, Cooperberg MR. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer. Cancer. 2024 May 15; 130(10):1766-1772.  View on PubMed
  19. Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024 01 04; 14(1):486.  View on PubMed
  20. Guan A, Santiago-Rodríguez EJ, Chung BI, Shim JK, Allen L, Kuo MC, Lau K, Loya Z, Brooks JD, Cheng I, DeRouen MC, Frosch DL, Golden T, Leppert JT, Lichtensztajn DY, Lu Q, Oh D, Sieh W, Wadhwa M, Cooperberg MR, Carroll PR, Gomez SL, Shariff-Marco S. Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study. BMC Cancer. 2023 Dec 05; 23(1):1191.  View on PubMed

Go to UCSF Profiles, powered by CTSI